Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Christoph Röllig on AML research in Dresden, Germany

Christoph Röllig • 1 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Daunorubicin
DaunoDouble

Christoph Röllig, MD, MSc, discusses the ongoing research into acute myeloid leukemia (AML) at his insitute, Dresden University of Technology, Dresden, Germany. He highlights the coordination of clinical trials, treatment sites and registries. Dr Röllig also discusses the DaunoDouble trial (NCT02140242), with further results expected to be presented at ASH 2019. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Christoph Röllig

2:19
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML
Christoph Röllig • 11 Dec 2023
1:45
HAM-Ven as salvage treatment for R/R AML: results from the SAL-RELAX trial
Christoph Röllig • 11 Dec 2023
2:26
Improving long-term outcomes with intensive chemotherapy in AML: looking to the future
Christoph Röllig • 11 Dec 2023
2:05
Results from the Phase I SAL-RELAX trial: venetoclax plus cytarabine and mitoxantrone in R/R AML
Christoph Röllig • 10 Dec 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals